Locally injected mesenchymal stem cells (MSCs) are now an approved therapy in European Union for perianal Crohn’s disease (CD) fistulas, however, clinical studies have shown limited efficacy of systemic MSC therapy for luminal CD. Thus, we studied the SAMP-1/YitFc (SAMP), a chronic and spontaneous murine model of small intestine (SI) inflammation for treatment with human bone marrow derived MSC (hMSC). We previously reported that hMSCs injected intraperitoneally (i.p) into SAMP resulted in histologic, mucosal and radiologic healing (Dave M et al.